文献速递自身免疫性与大疱性皮肤病

大疱性类天疱疮结局测量的范围综述:结局异质性与治疗研究趋势

Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments.
PubMed 文献 · Br J Dermatol · 2026-01-01

该范围综述检索2002年1月至2025年8月的科学数据库与试验注册库,纳入80项研究(临床试验27项、前瞻性队列27项、系统综述26项),逐字提取659个结局并归入10个结局领域区域的46个结局域。结果显示临床应答、安全性和免疫学应答占主要部分,临床应答定义与时间点差异很大,患者报告结局(PROs)偏少,尽管有标准化努力,多数研究仍缺乏定义明确且一致的结局。

要点

  • BP治疗研究结局与测量工具高度异质,临床应答定义和时间点差异明显。
  • 患者报告结局与生活质量测量偏少且多为通用工具,与医生报告结局不平衡。
  • 建议通过共识统一结局定义,兼顾监管要求、验证性敏感测量与PROs。

核心结论

  • 过去二十年BP研究报道的结局与结局测量工具存在相当大的异质性,多数研究缺乏定义明确且一致的结局。
  • 应重新定义部分终点并以共识方式推进结局统一,以衔接监管要求与验证性敏感测量及PROs。

研究设计与样本

  • 范围综述,检索科学数据库与试验注册库(2002年1月至2025年8月),由至少两名评审独立完成研究选择与数据提取。
  • 纳入临床试验、前瞻性队列研究和系统综述,排除回顾性研究;共纳入80项研究(临床试验27项、前瞻性队列27项、系统综述26项)。

主要发现

  • 逐字提取659个结局,分类为10个结局领域区域下的46个结局域。
  • 临床应答、安全性和免疫学应答构成结局测量的主要部分,临床试验中越来越考虑类固醇毒性。
  • 临床应答的定义和时间点差异很大,PROs占少数,且临床试验主要分析与系统综述次要分析关注点存在分歧。
  • 用于测量患者影响和生活质量的OMIs主要为通用工具且使用稀少。

临床怎么用

  • 解读BP治疗证据时需注意各研究对临床应答定义与时间点不一致,结局难以直接合并比较。
  • 关注类固醇毒性等安全性结局,并在研究中补充经验证的患者报告结局与生活质量测量。
  • 推动采用共识统一的结局与测量工具,以提升试验终点的临床相关性和研究间可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune bullous disease. It is characterized by the development of tense blisters and pruritus. BP is a chronic disease that requires long-term treatment often associated with serious side effects. Developments in understanding the disease have led to novel treatment approaches evaluated in clinical trials. However, the pooling of trial data remains challenging due to inconsistent outcome reporting. OBJECTIVES: To provide an overview of BP outcome measurement over the last two decades by mapping and listing all previously reported treatment outcomes and outcome measurement instruments (OMIs). METHODS: A large scoping review was performed using scientific databases and trial registries (January 2002-August 2025). Study selection and data extraction were performed independently by a minimum of two reviewers. Eligible study designs were clinical trials, prospective cohort studies and systematic reviews. Retrospective studies were excluded. All identified outcomes and OMIs were mapped into overarching domains for insights into outcome measurement trends over time, including the uptake of consensus definitions. RESULTS: Eighty studies were included, consisting of clinical trials (n = 27), prospective cohort studies (n = 27) and systematic reviews (n = 26). A total of 659 outcomes were extracted verbatim and classified into 46 outcome domains across 10 outcome domain areas. Clinical response, safety and immunological response comprised a major part of outcome measurement. Moreover, steroid toxicity has increasingly been considered in clinical trials. Definitions and timepoints of clinical response varied considerably. An imbalance between patient-reported (PROs) and clinician-reported outcomes was revealed, with PROs being in the minority, as well as a diverging focus between primary analyses in clinical trials and secondary analyses in systematic reviews. OMIs used to measure patient impact and quality of life were mainly generic and only sparsely used. CONCLUSIONS: Over the past two decades, there has been considerable heterogeneity in reported outcomes and OMIs in BP research. Despite standardization efforts, most studies lack well-defined, consistent outcomes. Redefinition of some endpoints and a consensus-based approach towards outcome uniformity should bridge regulatory requirements with validated sensitive measurement and PROs. This approach would enhance the clinical relevance of trial endpoints while maintaining standardization, ultimately advancing research quality and therapeutic development. Bullous pemphigoid is a rare but serious skin condition. It causes large, fluid-filled blisters and severe itching on the skin. It mainly affects older adults and requires long-term treatment with medications. These medications can have serious side effects in people who take them. Between 2 and 23 people in a million develop the condition each year worldwide. We carried out a large review of studies of the disease published from 2002 to 2025. We did this to try to understand how researchers measure how effective treatment is. Our international research team looked at three types of studies. The first type of study was clinical trials that tested new treatments. Studies that followed groups of patients over time were also included. Finally, we included review articles that combined the results of many studies. We looked at 80 different studies of bullous pemphigoid. We found that researchers measured the effect of treatment in many ways. They looked at how well treatments cleared the blisters, whether there were any side effects and how the patient’s immune system responded. Steroids are often used to treat the condition. We noted that researchers paid attention to problems caused by steroid medications. We found some important gaps in current research. While researchers often reported the doctor’s findings on the effect of treatment, few studies asked patients about their experiences or quality of life. We also found that studies defined ‘treatment success’ differently. This makes it hard to compare the results of different studies. These findings suggest that researchers need to agree on standard ways to measure how effective treatment is. This would make it easier to compare different treatments and ensure that what matters most to patients is measured. This could lead to better treatments and improved care for people with the condition.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hiel MAJ, Tedbirt B, Korte EWH, et al. Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments. Br J Dermatol. 2026. PMID: 41290360. doi:10.1093/bjd/ljaf471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。